血管内皮生长因子/血管内皮生长因子受体通路在胆管细胞癌发生发展及治疗中的作用

Role of the VEGF/VEGFR pathways in the development,progression,and treatment of cholangiocellular carcinoma

胆管细胞癌(CCA)是源于胆道上皮的恶性肿瘤,缺乏有效的治疗药物,预后不良。研究表明,CCA的发生发展离不开血管生成,以血管内皮生长因子(VEGF)及其受体VEGFR为代表的多种促血管生成因子,均可调节CCA血管生成,参与CCA发生发展并影响其预后。因此,以VEGF/VEGFR为靶点的抗血管生成药物,包括单克隆抗体、小分子抑制剂等,逐渐成为CCA治疗的研究热点。针对VEGF/VEGFR通路在CCA临床特征及预后中的作用、CCA抗血管生成治疗进展及耐药相关研究进行综述。

Cholangiocellular carcinoma(CCA)is a malignant tumor derived from the biliary epithelium,with a lack of effective therapeutic drugs and poor prognosis.Studies have shown that the development and progression of CCA are closely associated with angiogenesis,and a variety of angiogenic factors,including vascular endothelial growth factor(VEGF)and its receptor VEGFR,can regulate angiogenesis in CCA,participate in the development and progression of CCA,and affect its prognosis.Therefore,anti-angiogenic drugs targeting VEGF/VEGFR,such as monoclonal antibodies and small-molecule inhibitors,have gradually become research hotspots for the treatment of CCA.This article reviews the role of the VEGF/VEGFR pathways in the clinical features and prognosis of CCA,the advances in anti-angiogenic therapy for CCA,and related studies on drug resistance.